¼¼°èÀÇ º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀå : Á¦Ç°º°, ¿ëµµº°, ±¹°¡º°, Áö¿ªº°-»ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2023-2030³â)
Combination Drugs Diagnostic Market, By Product Type, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
»óǰÄÚµå : 1397092
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2023³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 303 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,589,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,565,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,977,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

º¹ÇÕ ¾à¹° Áø´Ü(Combination Drugs Diagnostic) ½ÃÀå-½ÃÀå ¿ªÇÐ

½ÃÀ强Àå ÃËÁø·ÂÀº ³ëÀÎ Áõ°¡¿Í Áø´Ü±â¼ú Áøº¸¿¡ ÀÖÀ» °ÍÀ¸·Î ¿¹Ãø

°í·ÉÈ­ »çȸ¿¡´Â º¸´Ù Á¾ÇÕÀûÀÎ °Ç°­ °ü¸® ¼Ö·ç¼ÇÀÌ ÇÊ¿äÇϸç, ÀÌ¿¡ ´ëóÇÏ´Â Á¢±Ù¹ý Áß Çϳª°¡ Áø´Ü ±â´ÉÀ» ÅëÇÕÇÑ Á¦Á¦ÀÔ´Ï´Ù. ÀÌ ¾àÀº ³ëÀÎÀÇ °Ç°­ °ü¸®¿¡ Á¾ÇÕÀûÀÎ Á¢±ÙÀ» Á¦°øÇÕ´Ï´Ù. ¼¼°èº¸°Ç±â±¸´Â 2030³â±îÁö ¼¼°è 6¸í Áß 1¸íÀÌ 60¼¼ ÀÌ»óÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøÇϰí, ±× °á°ú 60¼¼ ÀÌ»óÀÇ Àα¸´Â 2020³â 10¾ï¸í¿¡¼­ 14¾ï¸íÀ¸·Î Áõ°¡ µË´Ï´Ù. Áø´ÜÇÐÀÇ Áøº¸¿¡ ÀÇÇØ Áúº´À̳ª º´ÅÂÀÇ Á¶±â ¹ß°ßÀÌ °¡´ÉÇÏ°Ô µÇ¾î, ½Ã±â ÀûÀýÇÑ °³ÀÔ, Áúº´ÀÇ Ãʱ⠴ܰ迡¼­ÀÇ º¹ÇÕ ¾à¹° ¿ä¹ýÀÇ °³½Ã°¡ °¡´ÉÇÏ°Ô µË´Ï´Ù. ±×·¯³ª COVID-19 ÆÒµ¥¹Íµµ ÀÌ »ó½Â¿¡ ±â¿©Çϰí ÀÖ¾î ¿ø°ÝÁøÂû ¿¹¾à, ȯÀÚ ¸ð´ÏÅ͸µ, ¿ø°Ý ÀÇ·á ¼­ºñ½ºÀÇ Ã¤ÅÃÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÇöÀç 30¾ï¸íÀ» µ¹ÆÄÇØ 2023³â¿¡´Â 40¾ï¸íÀ» ³ÑÀ» °ÍÀ¸·Î ¿¹ÃøµÇ´Â ½º¸¶Æ®Æù »ç¿ëÀÚ Áõ°¡°¡ ÇコÄÉ¾î ¾ÛÀÇ Àα⸦ ´õ¿í ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á±â¼ú Åë°è¿¡ µû¸£¸é ÇöÀç ¹Ì±¹ÀÎ 5¸í Áß 1¸íÀÌ ÇÇÆ®´Ï½º Æ®·¡Ä¿¿Í ½º¸¶Æ® ¿öÄ¡¸¦ ÀÌ¿ëÇϰí ÀÖÀ¸¸ç, ÀÌ ¼öÄ¡´Â 2025³â±îÁö 20% Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ±â¼ú°ú ÀǾàǰ °³¹ßÀÇ ÀÌ·¯ÇÑ Áøº¸´Â Çõ½ÅÀûÀÎ Á¦Á¦¸¦ ¸¸µé ¼öÀÖ´Â ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±×·¯³ª Áø´ÜÁ¦ ¼ººÐÀ» Æ÷ÇÔÇÑ Á¦Á¦¿¡ ´ëÇÑ »óȯ Á¤Ã¥À» ¼ö¸³ÇÏ´Â °ÍÀÌ °úÁ¦°¡ µÉ ¼ö ÀÖ½À´Ï´Ù.

º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀå-ÁÖ¿ä ÀλçÀÌÆ®

¿ì¸®ÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ® ºÐ¼®¿¡ µû¸£¸é ¼¼°èÀÇ º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀåÀº ¿¹Ãø ±â°£(2023-2030³â)¿¡ ¾à 9.2%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

°¡Ã³ºÐ ¼Òµæ Áõ°¡¿Í Á¦Çü¿¡ ´ëÇÑ ÀǽÄÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º¹ÇÕ ¾à¹° Áø´Ü ºÐ¾ß´Â »ó´çÇÑ ¼ºÀåÀ» ±â´ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­¿¡ ±Ù°ÅÇϸé Ç×±Õ Ä«Å×ÅͰ¡ 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿ëµµº°·Î °¨¿°Àº 2022³âÀÇ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2022³â¿¡ ¼öÀÍÀ» ¿Ã¸®´Â ÁÖ¿ä ½ÃÀåÀ̾ú½À´Ï´Ù.

º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀå-¼¼ºÐÈ­ ºÐ¼® :

º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀåÀº Á¦Ç°, ¿ëµµ ¹× Áö¿ª¿¡ µû¶ó ±¸ºÐµË´Ï´Ù.

½ÃÀåÀº Á¦Ç°¿¡ µû¶ó ¼¼ºÐÈ­ µË´Ï´Ù : ÃÊÀ½ÆÄ, Ç×±Õ Ä«Å×ÅÍ, ½ÉÇ÷°ü Ä«Å×ÅÍ, ºñ´¢±â Ä«Å×ÅÍ, »ê¼Ò ÃøÁ¤ Ä«Å×ÅÍ, »À ÀÌ½Ä ´ëü, Æ÷¸£ÇÇ¸Ó ³ªÆ®·ý ¹× ½ºÅ×·ÎÀ̵å, ¿ëÃâ Àü±Ø. ÇöÀç ½ÃÀåÀº Ç×±Õ Ä«Å×ÅͰ¡ Áö¹èÀûÀÔ´Ï´Ù. ±×·¯³ª Áø´ÜÁ¦, Á¦Á¦ ¿ä¹ý, Ç×±Õ Ä«Å×Å͸¦ Æ÷ÇÔÇÑ Á¾ÇÕÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ±â¾÷Àº °Ç°­ °ü¸®¿¡¼­ °¨¿° ¿¹¹æÀÇ º¹ÀâÇÑ ¹®Á¦¸¦ ÇØ°áÇϰí ÀáÀçÀûÀÎ ±âȸ¸¦ ÀâÀ» ¼ö ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¿ëµµº°·Î ¼¼ºÐÈ­ µË´Ï´Ù : °¨¿°, ½ÉÇ÷°ü Áúȯ, Á¤½Å Áúȯ, È£Èí±â Áúȯ. ½ÃÀåÀº °¨¿°¿¡ Å©°Ô ¿µÇâÀ» ¹Þ½À´Ï´Ù. °¨¿°ÀÇ ¿µ¿ª¿¡¼­´Â ÀǾàǰ°ú Áø´ÜÁ¦ÀÇ À¶ÇÕÀÌ Áß¿äÇÑ ¿ä¼Ò°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ Á¾ÇÕÀûÀÎ Á¢±Ù¹ýÀº º´¿øÃ¼¿Í °³º° ȯÀÚÀÇ ¹ÝÀÀ Ư¼ºÀ» °í·ÁÇÑ º¸´Ù Á¤È®Çϰí ÃÊÁ¡À» ¸ÂÃá Ä¡·á °èȹÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù.

º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀå-Áö¸®Àû ÅëÂû

Áö¿ªÀûÀ¸·Î º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀåÀº ºÏ¹Ì, ³²¹Ì, À¯·´, ¾Æ½Ã¾Æ ÅÂÆò¾ç, Áßµ¿, ¾ÆÇÁ¸®Ä« µî ´Ù¾çÇÑ Áö¿ªÀ¸·Î ÆÛÁ® ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº »ç¾÷ Ȱµ¿¿¡ °ü¿©ÇÏ´Â ±¹°¡¿¡ µû¶ó Ãß°¡·Î ºÐ·ùµË´Ï´Ù. º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î R&D »ç¾÷¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ºÏ¹Ì°¡ Áö¹èÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºÏ¹Ì, ƯÈ÷ ¹Ì±¹Àº Á¦¾à ¹× »ý¸í °øÇÐ ¿¬±¸ °³¹ßÀÇ ¼¼°è Áß½ÉÁö·Î Àνĵǰí ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ß»ç¾÷¿¡ ´ëÇÑ ¸¹Àº ÅõÀÚ´Â Áø´Ü¾à ¼ººÐÀ» Æ÷ÇÔÇÑ Çõ½ÅÀûÀÎ ¹èÇÕ¾àÀÇ °³¹ß¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹°úÇÐÀç´ÜÀÇ ¹Ì±¹°úÇбâ¼úÅë½Å¼¾ÅÍ(NCSES)¿¡ µû¸£¸é ¹Ì±¹ÀÇ R&D Ȱµ¿¿¡ ´ëÇÑ ÃÑ ÁöÃâÀº 2020³â 7,170¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. À¯·´Àº ¾Ï, ½ÉÀ庴, ´ç´¢º´ µî ¸¸¼º Áúȯ Áõ°¡·Î 2À§ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀå-°æÀï ±¸µµ :

º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀåÀÇ °æÀï ȯ°æÀº ¿ªµ¿ÀûÀ̸ç, ¸¹Àº ±â¾÷µéÀÌ º¹ÇÕ ¾à¹° Ä¡·á¿¡ ´ëÇÑ ÁöħÀÌ µÇ´Â Áø´Ü µµ±¸ÀÇ °³¹ß°ú »ó¾÷È­¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °¢ Á¦Á¶¾÷ü´Â º¹ÇÕ ¾à¹° Ä¡·á¸¦ Áö¿øÇÏ´Â Áø´Ü ¾à¹° °³¹ß¿¡ Àû±ØÀûÀ¸·Î ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó ÇöÀå¿¡¼­ µµÀԵǰí ÀÖ´Â ½Å¼¼´ë Ç¥Àû ¿ä¹ýÀÇ »ó´ç ºÎºÐÀº ÄÄÆÐ´Ï¾ð Áø´ÜÁ¦·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ±× ¿ä¹ýÀÇ ÀûÀÀ¿¡ ÇʼöÀûÀÎ °Ë»ç¸¦ ȯÀÚ°¡ ¹ÞÀ» °ÍÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º¸¿Ï Áø´ÜÀ̶ó°í ÇÏ´Â Ä¡·á Á¤Ã¥ °áÁ¤À» Áö¿øÇÏ´Â °Ë»ç°¡ ÀÖÁö¸¸ ó¹æÀü¿¡´Â Çʼö´Â ¾Æ´Õ´Ï´Ù. ÀÌ·¯ÇÑ Á¦¾àȸ»çÀÇ ½Å¾à°³¹ß¹æ¹ýÀÇ º¯È­·Î ÀÎÇØ ¾à»ç ½ÂÀÎÀ» ¿ä±¸ÇÏ´Â ¾àÁ¦¿Í Áø´Ü¾à Á¶ÇÕÀÇ ¼ö°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °³º° ȯÀÚÀÇ Æ¯¼º¿¡ ¸Â°Ô Ä¡·á Á¤Ã¥À» °áÁ¤ÇÏ´Â °³ÀÎÈ­µÈ ÀÇ·á¿¡ ´ëÇÑ µ¿Çâ Áõ°¡´Â º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀåÀÇ Å« ÃËÁø·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ Áø´Ü±â¼ú°ú À̹Ì¡ ºÐ¾ßÀÇ Áö¼ÓÀûÀÎ ±â¼úÁøº¸´Â °æÀï ±¸µµ Çü¼º¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀå-ÁÖ¿ä µ¿Çâ

Á¦4Àå º¹ÇÕ ¾à¹° Áø´Ü »ê¾÷ Á¶»ç

Á¦5Àå º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀå »óȲ

Á¦7Àå º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀå : Á¦Ç°º°

Á¦8Àå º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀå : ¿ëµµº°

Á¦9Àå º¹ÇÕ ¾à¹° Áø´Ü ½ÃÀå : Áö¿ªº°

Á¦10Àå ÁÖ¿ä º¥´õ ºÐ¼® : º¹ÇÕ ¾à¹° Áø´Ü »ê¾÷

Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

The combination medications and diagnostic tools plays a crucial role in modern healthcare, particularly in the realm of personalized medicine and targeted therapies. A combination product refers to a therapeutic or diagnostic product that combines drugs, medical devices, and/or biological products. Such products typically involve at least two of these categories and sometimes encompass all three. Common examples include traditional drug-device combinations, such as a syringe pre-filled with medication, as well as co-packaged or kitted products, like a first-aid kit containing bandages and pain-relieving medications. In the healthcare field, diagnostics pertain to the identification of the nature and cause of a disease or condition. Diagnostic tools encompass various techniques, including imaging, laboratory tests, and other medical assessments.

Combination Drugs Diagnostic Market- Market Dynamics

The market growth is anticipated to be driven by the increasing number of elderly individuals and advancements in diagnostic techniques.

Aging populations necessitate more comprehensive healthcare solutions, and one approach to address this is through combination drugs that incorporate diagnostic capabilities. These drugs offer a holistic approach to managing the health of elderly individuals. The World Health Organization predicts that by 2030, 1 in 6 people worldwide will be aged 60 years or over, resulting in an increase in the population aged 60 years and over from 1 billion in 2020 to 1.4 billion. The advancement of diagnostics allows for the early detection of diseases and conditions, enabling timely intervention and the initiation of combination drug therapies at the earliest stages of illnesses. However, the COVID-19 pandemic has also contributed to this rise, with the adoption of remote doctor's appointments, patient monitoring, and telehealth services. The increasing number of smartphone users, which has surpassed 3 billion today and is projected to exceed 4 billion by 2023, has further boosted the popularity of healthcare apps. Additionally, medical technology statistics indicate that 1 in 5 Americans currently utilize fitness trackers or smartwatches, a number expected to grow by 20% by 2025. These advancements in medical technology and drug development present opportunities for the creation of innovative combination drugs. However, establishing reimbursement policies for combination drugs that include diagnostic components can pose a challenge.

Combination Drugs Diagnostic Market- Key Insights

Combination Drugs Diagnostic Market- Segmentation Analysis:

The Global Combination Drugs Diagnostic Market is segmented on the basis of Product Type, Application, and Region.

The market is divided into three categories based on product type: Ultrasound, Antimicrobial catheters, Cardiovascular catheters, urological catheters, Oximetry catheters, Bone graft substitutes, Porfimer sodium & steroid and Eluting electrodes. The market is currently dominated by antimicrobial catheters. However, companies that provide comprehensive solutions, including diagnostics, combination drug therapies, and antimicrobial catheters, may be able to tackle the intricate issues of infection prevention in healthcare and seize potential opportunities.

The market is divided into two categories based on application: Infectious Diseases, Cardiovascular Diseases, Psychiatric Disorders, and Respiratory Disorders. The market is largely influenced by Infectious Diseases. The amalgamation of drugs and diagnostics is proving to be a crucial factor in the realm of infectious diseases. This comprehensive approach facilitates more accurate and focused treatment plans, taking into account the unique features of pathogens and individual patient reactions.

Combination Drugs Diagnostic Market- Geographical Insights

Geographically, the market for Combination Drugs Diagnostics is spread across various regions including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further categorized based on the countries involved in business activities. The growth of the Combination Drugs Diagnostic market is expected to be dominated by North America, primarily due to the increasing investments in research and development (R&D) operations. North America, especially the United States, is recognized as a global center for pharmaceutical and biotechnology R&D. The substantial investments in R&D operations contribute to the development of innovative combination drugs that incorporate diagnostic components. According to the National Center for Science and Engineering Statistics (NCSES) within the National Science Foundation, the total expenditure on R&D activities in the United States reached USD 717.0 billion in 2020. Europe holds the second-largest market share, driven by the rising prevalence of chronic diseases such as cancer, heart disease, and diabetes.

Combination Drugs Diagnostic Market- Competitive Landscape:

The landscape of the market for combination drug diagnostics has been dynamic, with numerous companies contributing to the advancement and commercialization of diagnostic tools for guiding combination drug therapies. The manufacturers are actively involved in developing diagnostics that support combination drug therapies. A significant portion of the new generation of targeted therapies being introduced in clinical settings require patients to undergo essential tests that are necessary for the therapy's indication, known as companion diagnostics. Additionally, there are tests known as complementary diagnostics that support treatment decisions but are not essential prior to prescription. This shift in the way pharmaceutical companies develop new medicines has led to a significant increase in the number of drug-diagnostic combinations seeking regulatory approval. The growing trend towards personalized medicine, where treatment decisions are tailored to individual patient characteristics, is a major driving force in the combination drugs diagnostic market. Ongoing technological advancements, particularly in diagnostic technologies and imaging, play a crucial role in shaping the competitive landscape.

Recent Developments:

Roche's Columvi has been granted FDA approval as a third-line treatment for diffuse large B-cell lymphoma, a type of blood cancer. This new drug will now compete with AbbVie's Epkinly, which was recently approved for the same condition. The approval of Roche's new drug provides patients with another therapeutic option.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL COMBINATION DRUGS DIAGNOSTIC MARKET KEY PLAYERS

GLOBAL COMBINATION DRUGS DIAGNOSTIC MARKET, BY PRODUCT TYPE

GLOBAL COMBINATION DRUGS DIAGNOSTIC MARKET, BY APPLICATION

GLOBAL COMBINATION DRUGS DIAGNOSTIC MARKET, BY REGION

Table of Contents

1. Combination Drugs Diagnostic Market Overview

2. Executive Summary

3. Combination Drugs Diagnostic Key Market Trends

4. Combination Drugs Diagnostic Industry Study

5. Combination Drugs Diagnostic Market: COVID-19 Impact Analysis

6. Combination Drugs Diagnostic Market Landscape

7. Combination Drugs Diagnostic Market - By Product Type

8. Combination Drugs Diagnostic Market - By Application

9. Combination Drugs Diagnostic Market- By Geography

10. Key Vendor Analysis- Combination Drugs Diagnostic Industry

11. 360 Degree Analyst View

12. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â